Nanomedicine as a Potential Tool against Monkeypox
Human monkeypox is a rare viral zoonosis that was first identified in 1970; since then, this infectious disease has been marked as endemic in central and western Africa. The disease has always been considered rare and self-limiting; however, recent worldwide reports of several cases suggest otherwis...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-02-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/11/2/428 |
| _version_ | 1827755284755382272 |
|---|---|
| author | Nura Adam Mohamed Luisa Zupin Sarah Ismail Mazi Hebah A. Al-Khatib Sergio Crovella |
| author_facet | Nura Adam Mohamed Luisa Zupin Sarah Ismail Mazi Hebah A. Al-Khatib Sergio Crovella |
| author_sort | Nura Adam Mohamed |
| collection | DOAJ |
| description | Human monkeypox is a rare viral zoonosis that was first identified in 1970; since then, this infectious disease has been marked as endemic in central and western Africa. The disease has always been considered rare and self-limiting; however, recent worldwide reports of several cases suggest otherwise. Especially with monkeypox being recognized as the most important orthopoxvirus infection in humans in the smallpox post-eradication era, its spread across the globe marks a new epidemic. Currently, there is no proven treatment for human monkeypox, and questions about the necessity of developing a vaccine persist. Notably, if we are to take lessons from the COVID-19 pandemic, developing a nanomedicine-based preventative strategy might be prudent, particularly with the rapid growth of the use of nanotechnology and nanomaterials in medical research. Unfortunately, the collected data in this area is limited, dispersed, and often incomplete. Therefore, this review aims to trace all reported nanomedicine approaches made in the monkeypox area and to suggest possible directions that could be further investigated to develop a counteractive strategy against emerging and existing viruses that could diminish this epidemic and prevent it from becoming a potential pandemic, especially with the world still recovering from the COVID-19 pandemic. |
| first_indexed | 2024-03-11T08:02:09Z |
| format | Article |
| id | doaj.art-c33f46399d724e778961ced23d34062d |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-11T08:02:09Z |
| publishDate | 2023-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-c33f46399d724e778961ced23d34062d2023-11-16T23:44:16ZengMDPI AGVaccines2076-393X2023-02-0111242810.3390/vaccines11020428Nanomedicine as a Potential Tool against MonkeypoxNura Adam Mohamed0Luisa Zupin1Sarah Ismail Mazi2Hebah A. Al-Khatib3Sergio Crovella4Biomedical Research Center (BRC), Qatar University, Doha P.O. Box 2713, QatarInstitute for Maternal and Child Health IRCCS Burlo Garofolo, 34137 Trieste, ItalyDepartment of Cardiac Sciences, College of Medicine, King Saud University, P.O. Box 7805, Riyadh 11472, Saudi ArabiaBiomedical Research Center (BRC), Qatar University, Doha P.O. Box 2713, QatarBiological Science Program, Department of Biological and Environmental Sciences, College of Arts and Sciences, Qatar University, Doha P.O. Box 2713, QatarHuman monkeypox is a rare viral zoonosis that was first identified in 1970; since then, this infectious disease has been marked as endemic in central and western Africa. The disease has always been considered rare and self-limiting; however, recent worldwide reports of several cases suggest otherwise. Especially with monkeypox being recognized as the most important orthopoxvirus infection in humans in the smallpox post-eradication era, its spread across the globe marks a new epidemic. Currently, there is no proven treatment for human monkeypox, and questions about the necessity of developing a vaccine persist. Notably, if we are to take lessons from the COVID-19 pandemic, developing a nanomedicine-based preventative strategy might be prudent, particularly with the rapid growth of the use of nanotechnology and nanomaterials in medical research. Unfortunately, the collected data in this area is limited, dispersed, and often incomplete. Therefore, this review aims to trace all reported nanomedicine approaches made in the monkeypox area and to suggest possible directions that could be further investigated to develop a counteractive strategy against emerging and existing viruses that could diminish this epidemic and prevent it from becoming a potential pandemic, especially with the world still recovering from the COVID-19 pandemic.https://www.mdpi.com/2076-393X/11/2/428monkeypoxnanomedicinevaccine |
| spellingShingle | Nura Adam Mohamed Luisa Zupin Sarah Ismail Mazi Hebah A. Al-Khatib Sergio Crovella Nanomedicine as a Potential Tool against Monkeypox Vaccines monkeypox nanomedicine vaccine |
| title | Nanomedicine as a Potential Tool against Monkeypox |
| title_full | Nanomedicine as a Potential Tool against Monkeypox |
| title_fullStr | Nanomedicine as a Potential Tool against Monkeypox |
| title_full_unstemmed | Nanomedicine as a Potential Tool against Monkeypox |
| title_short | Nanomedicine as a Potential Tool against Monkeypox |
| title_sort | nanomedicine as a potential tool against monkeypox |
| topic | monkeypox nanomedicine vaccine |
| url | https://www.mdpi.com/2076-393X/11/2/428 |
| work_keys_str_mv | AT nuraadammohamed nanomedicineasapotentialtoolagainstmonkeypox AT luisazupin nanomedicineasapotentialtoolagainstmonkeypox AT sarahismailmazi nanomedicineasapotentialtoolagainstmonkeypox AT hebahaalkhatib nanomedicineasapotentialtoolagainstmonkeypox AT sergiocrovella nanomedicineasapotentialtoolagainstmonkeypox |